Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

PET Study in Parkinson's Disease Patients

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: December 22, 2011
Last updated: January 30, 2013
Last verified: January 2013
This is a multi-centre study to be conducted in Sweden and Finland. Up to 24 male and/or female patients of non-childbearing potential aged 45 to 75 years (inclusive), with a clinical diagnosis Parkinson's Disease will be randomised in the study to allow for 20 patients to complete this study.The study will evaluate the effect of 8 weeks treatment with AZD3241 on microglia activation as measured via PET examinations.

Condition Intervention Phase
Parkinson's Disease
Drug: ER tablet 25 mg AZD3241
Drug: ER tablet 100 mg AZD3241
Drug: Placebo for AZD3241 25 mg
Drug: Placebo for AZD3241 100 mg
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase IIA, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment With Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients With Parkinson's Disease

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change of binding [11C]PBR28 to translocator protein (TSPO) measured by Positron Emission Tomography (PET). [ Time Frame: baseline, 2-4 weeks ]
  • Change of binding of [11C]PBR28 to TSPO measured by PET. [ Time Frame: baseline, 7-8 weeks ]

Secondary Outcome Measures:
  • Adverse events, vital signs, electrocardiogram (ECG), physical examination, clinical chemistry tests, height and weight measures for safety and tolerability profile. [ Time Frame: Up to 10 weeks ]
  • Change in plasma activity of myeloperoxidase (MPO). [ Time Frame: baseline, up to 10 weeks ]
  • Plasma concentrations of AZD3241. [ Time Frame: Up to 8 weeks ]
  • Part of safety profile in terms of Columbia Suicide Severity Rating Scale. [ Time Frame: Up to 10 weeks ]

Enrollment: 24
Study Start Date: April 2012
Study Completion Date: January 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZD3241
AZD3241 tablets 25 mg or 100 mg, titration first 5 days (50 mg bd on Day 1, 100 mg bd on Day 2, 200 mg bd on Day 3, 300 mg bd on Day 4, 400 mg bd on Day 5) Maintenance treatment from Day 6, 600 mg bd until Day 56±3 days
Drug: ER tablet 25 mg AZD3241
2 tablets twice daily for Day 1
Drug: ER tablet 100 mg AZD3241
1-6 tablets twice daily from Day 2 until Day 56±3 days
Experimental: Placebo
AZD3241 placebo bid for 8 weeks
Drug: Placebo for AZD3241 25 mg
2 tablets twice daily for Day 1
Drug: Placebo for AZD3241 100 mg
1-6 tablets twice daily from Day 2 until Day 56±3 days

Detailed Description:
A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson's Disease

Ages Eligible for Study:   45 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female and male patients aged 45 to 75 years (inclusive) at the day of enrolment (Visit 1)
  • Female patients must have a negative pregnancy test at Screening, must not be lactating and must be of non childbearing potential, confirmed at Screening
  • Male patients should be willing to use barrier contraception, eg, condoms, even if their partners are post-menopausal, be surgically sterile or are using accepted contraceptive methods, from the administration of the first dose of the investigational
  • The clinical diagnosis of patients must meet the criteria for "diagnosis of idiopathic Parkinson's disease" according to the modified UKPDS Brain Bank criteria (see Appendix E)
  • Modified Hoehn and Yahr stage 1 to 2

Exclusion Criteria:

  • Diagnosis is unclear or a suspicion of other Parkinsonian syndromes exists, such as secondary Parkinsonism (caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), Parkinson-plus syndromes or heredodegenerative diseases
  • Patients who have undergone surgery for the treatment of Parkinson's disease (eg, pallidotomy, deep brain stimulation, foetal tissue transplantation) or have undergone any other brain surgery
  • Presence of significant dyskinesias, motor fluctuations, swallowing difficulties or loss of postural reflexes Patients with a history of non-response (according to both the clinician and the patient) to an adequate course of L-dopa or a DA agonist
  • Use of pergolide, selegiline, metoclopramide, strong CYP3A4 inhibitors, CYP3A4 inducers (including St John's Wort) and strong CYP1A2 inhibitors and inducers, within 1 month of randomisation;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01527695

Reserach Site
Stockholm, Sweden
Research Site
Uppsala, Sweden
Research Site
Vallingby, Sweden
Sponsors and Collaborators
Principal Investigator: Per Svenningsson, MD, PHD Karolinska University Hospital
Study Director: Bjorn Paulsson, MD AstraZeneca Medical Science Director
  More Information

Responsible Party: AstraZeneca Identifier: NCT01527695     History of Changes
Other Study ID Numbers: D0490C00004
Study First Received: December 22, 2011
Last Updated: January 30, 2013

Keywords provided by AstraZeneca:
Phase IIa
microglia activation
Pharmacodynamics and pharmacokinetics analyses
Parkinson patients

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases processed this record on May 25, 2017